Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? - Targeting hyperinflammation
Curr Med Res Opin. 2022 Jan 20:1-8. doi: 10.1080/03007995.2022.2027141. Online ahead of print.ABSTRACTSodium-glucose co-transporter-2 (SGLT-2) inhibitors are antidiabetic drugs with numerous pleiotropic and positive clinical effects, particularly regarding a reno-cardiovascular protective effect. More recent studies, including from our laboratory, have highlighted some novel anti-inflammatory activity of SGLT-2 inhibitors. This may confer a theoretical advantage in mitigating excessive cytokine production and inflammatory response associated with serious COVID-19 infection. Specifically, earlier research has demonstrated t...
Source: Current Medical Research and Opinion - January 21, 2022 Category: Research Authors: Afnan Alshnbari Iskandar Idris Source Type: research

Psychometric properties of the EQ-5D-3L in South Australia: a multi-method non-preference-based validation study
This study aims to psychometrically validate the EQ-5D-3L in a large population sample in Australia for the first time.METHODS: The EQ-5D-3L was included in the Dental Care and Oral Health study (DCOHS), conducted in a South Australian population sample. The participants were 23-91 years old, and 44.1% were male. The EQ-5D-3L was responded to on a three-point rating scale ("none"/"no", "some" and "extremely"/"unable"/"confined"). We employed the area under the receiver operating characteristic curve (AUROC) to evaluate whether the EQ-5D-3L total score could identify participants with diagnosed diseases and mental health di...
Source: Current Medical Research and Opinion - January 21, 2022 Category: Research Authors: Mehrsa Zakershahrak Pedro H Ribeiro Santiago Sneha Sethi Dandara Haag Lisa Jamieson David Brennan Source Type: research

Surgery versus hormone-based treatment for pain control in deep infiltrating endometriosis: a retrospective cohort study
Conclusion: Both types of treatment, surgical and pharmacological, effectively improved pain symptoms associated with DIE. However, improvement in chronic pelvic pain, dyschezia and deep dyspareunia was greater and longer lasting after surgery.PMID:35060442 | DOI:10.1080/03007995.2022.2031940 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 21, 2022 Category: Research Authors: Gabriela Pravatta Rezende Marina Capovilla Venturini Lucas Nobushy Kawagoe Daniela Angerame Yela Gomes Cristina Laguna Benetti-Pinto Source Type: research

Defining utility values for patients with tardive dyskinesia
CONCLUSIONS: Utility decrements for TD in this study were slightly larger than previously reported values, potentially due to incorporation of QOL and social consequences in TD health state descriptions. An important limitation of this analysis is that participants' willingness to trade future years of healthy life may not indicate actual willingness to accept the life decrement. These findings can be leveraged to improve cost-effectiveness analyses used to assess the value of treatments for TD.PMID:35045768 | DOI:10.1080/03007995.2021.2022918 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 20, 2022 Category: Research Authors: Rajeev Ayyagari Debbie Goldschmidt Mo Zhou Rinat Ribalov Stanley N Caroff Sam Leo Source Type: research

An interview on rare diseases and orphan medicines with Dr Daniel O'Connor, medical assessor at the Medicines and Healthcare products Regulatory Agency (MHRA), UK
Curr Med Res Opin. 2022 Jan 19:1-2. doi: 10.1080/03007995.2021.2023394. Online ahead of print.NO ABSTRACTPMID:35045782 | DOI:10.1080/03007995.2021.2023394 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 20, 2022 Category: Research Authors: Daniel O'Connor Source Type: research

The use of progestin subdermal implants in the management of endometriosis-related pain symptoms and quality of life: a systematic review
CONCLUSION: Etonogestrel- and segesterone-releasing progestin subdermal implants appear to improve endometriosis-related pain symptoms and quality of life, and may provide an additional component in the management of endometriosis. However, this systematic review is limited by a small sample size and heterogeneity in the data. As such, larger prospective randomized trials are needed to guide further management.PROSPERO Registration: CRD42021225665.PMID:35048754 | DOI:10.1080/03007995.2022.2031144 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 20, 2022 Category: Research Authors: Kristin Ambacher Michael Secter Ari P Sanders Source Type: research

An interview on rare and genetic diseases with Dr Bruce Korf, Associate Dean for Genomic Medicine at the University of Alabama at Birmingham
Curr Med Res Opin. 2022 Jan 20:1-3. doi: 10.1080/03007995.2021.2023395. Online ahead of print.NO ABSTRACTPMID:35048769 | DOI:10.1080/03007995.2021.2023395 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 20, 2022 Category: Research Authors: Bruce Korf Source Type: research

A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder
CONCLUSIONS: In the Asian real-world setting, vortioxetine showed greater improvements in depressive and cognitive symptoms, work functioning, and response and remission rates when used as first-line versus second-line treatment or later. Vortioxetine was well-tolerated irrespective of the study population across Asia.PMID:35049384 | DOI:10.1080/03007995.2022.2031146 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 20, 2022 Category: Research Authors: Rohini Bose Syed Usman Hamdani Fareed Aslam Minhas Keira Joann Herr Source Type: research

Defining utility values for patients with tardive dyskinesia
CONCLUSIONS: Utility decrements for TD in this study were slightly larger than previously reported values, potentially due to incorporation of QOL and social consequences in TD health state descriptions. An important limitation of this analysis is that participants' willingness to trade future years of healthy life may not indicate actual willingness to accept the life decrement. These findings can be leveraged to improve cost-effectiveness analyses used to assess the value of treatments for TD.PMID:35045768 | DOI:10.1080/03007995.2021.2022918 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 20, 2022 Category: Research Authors: Rajeev Ayyagari Debbie Goldschmidt Mo Zhou Rinat Ribalov Stanley N Caroff Sam Leo Source Type: research

An interview on rare diseases and orphan medicines with Dr Daniel O'Connor, medical assessor at the Medicines and Healthcare products Regulatory Agency (MHRA), UK
Curr Med Res Opin. 2022 Jan 19:1-2. doi: 10.1080/03007995.2021.2023394. Online ahead of print.NO ABSTRACTPMID:35045782 | DOI:10.1080/03007995.2021.2023394 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 20, 2022 Category: Research Authors: Daniel O'Connor Source Type: research

The use of progestin subdermal implants in the management of endometriosis-related pain symptoms and quality of life: a systematic review
CONCLUSION: Etonogestrel- and segesterone-releasing progestin subdermal implants appear to improve endometriosis-related pain symptoms and quality of life, and may provide an additional component in the management of endometriosis. However, this systematic review is limited by a small sample size and heterogeneity in the data. As such, larger prospective randomized trials are needed to guide further management.PROSPERO Registration: CRD42021225665.PMID:35048754 | DOI:10.1080/03007995.2022.2031144 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 20, 2022 Category: Research Authors: Kristin Ambacher Michael Secter Ari P Sanders Source Type: research

An interview on rare and genetic diseases with Dr Bruce Korf, Associate Dean for Genomic Medicine at the University of Alabama at Birmingham
Curr Med Res Opin. 2022 Jan 20:1-3. doi: 10.1080/03007995.2021.2023395. Online ahead of print.NO ABSTRACTPMID:35048769 | DOI:10.1080/03007995.2021.2023395 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 20, 2022 Category: Research Authors: Bruce Korf Source Type: research

A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder
CONCLUSIONS: In the Asian real-world setting, vortioxetine showed greater improvements in depressive and cognitive symptoms, work functioning, and response and remission rates when used as first-line versus second-line treatment or later. Vortioxetine was well-tolerated irrespective of the study population across Asia.PMID:35049384 | DOI:10.1080/03007995.2022.2031146 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 20, 2022 Category: Research Authors: Rohini Bose Syed Usman Hamdani Fareed Aslam Minhas Keira Joann Herr Source Type: research

An anchored simulated treatment comparison of uptitration of amlodipine compared with a low-dose combination treatment with amlodipine 5  mg/bisoprolol 5 mg for patients with hypertension suboptimally controlled by amlodipine 5 mg monotherapy
CONCLUSION: In this indirect comparison, a more important decrease was observed in DBP with the low-dose combination as compared to the alternative therapeutic approach of up-titration from amlodipine 5 mg to amlodipine 10 mg. No meaningful difference was seen for SBP.PMID:35042448 | DOI:10.1080/03007995.2022.2030112 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - January 19, 2022 Category: Research Authors: Caroline Foch Jan Feifel Ulrike Gottwald-Hostalek Source Type: research